AstraZeneca has reportedly made a non-binding offer of approximately $10 billion to acquire U.S.-based Rhythm Pharmaceuticals. The proposal is said to be worth up to $134 per share, including milestone-based payments. No definitive agreement has been announced. Rhythm develops therapies for rare neuroendocrine diseases. Its commercial product IMCIVREE (setmelanotide) is a melanocortin-4 receptor (MC4R) agonist […]
- info-gsls@greenstafflifesciences.com
- Mon - Fri: 9.00 - 18.00 (JST)
- Accessibility